C07K 2319/033
Containing a motif for targeting to the internal surface of the plasma
Official title: containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
C07K2319/033 (Containing a motif for targeting to the internal surface of the plasma) appears on 127 US grants and 212 published applications in this corpus.
Search patents in C07K- Granted patents
- 127
- Published applications
- 212
- Assignees
- 157
- Inventors
- 504
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 2 | 0 |
| 1992 | 3 | 0 |
| 1993 | 1 | 0 |
| 1994 | 2 | 0 |
| 1995 | 3 | 0 |
| 1996 | 4 | 0 |
| 1997 | 1 | 0 |
| 1998 | 6 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 3 | 6 |
| 2003 | 1 | 2 |
| 2004 | 3 | 3 |
| 2005 | 3 | 10 |
| 2006 | 4 | 4 |
| 2007 | 3 | 3 |
| 2008 | 3 | 1 |
| 2009 | 0 | 3 |
| 2010 | 1 | 3 |
| 2011 | 0 | 2 |
| 2012 | 2 | 6 |
| 2013 | 2 | 5 |
| 2014 | 3 | 6 |
| 2015 | 1 | 6 |
| 2016 | 5 | 1 |
| 2017 | 4 | 8 |
| 2018 | 3 | 11 |
| 2019 | 3 | 25 |
| 2020 | 7 | 21 |
| 2021 | 8 | 13 |
| 2022 | 13 | 14 |
| 2023 | 8 | 22 |
| 2024 | 8 | 18 |
| 2025 | 7 | 15 |
| 2026 | 7 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Fusion constructs and uses thereof1 Sep 2026US 12,723,071 B2B-Portal Biologics, Inc.
- Synthetic pathway activators14 Jul 2026US 12,679,881 B2Arsenal Biosciences, Inc.
- Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/PIV3 F protein and uses thereof2 Jun 2026US 12,643,925 B2The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Cell28 Apr 2026US 12,612,443 B2Autolus Limited
- Modified mini-nucleosome core proteins and use in nucleic acid delivery21 Apr 2026US 12,606,833 B2
- Fusion constructs and uses thereof24 Sep 2026US 2026/0285960 A1B-Portal Biologics, Inc.
- Synthetic pathway activators27 Aug 2026US 2026/0250355 A1Arsenal Biosciences, Inc.
- Anti-mage-a4 t cell receptors6 Aug 2026US 2026/0226134 A1Zelluna Immunotherapy AS
- Enhanced virus-like particles and methods of use thereof for delivery to cells22 Jan 2026US 2026/0022349 A1The General Hospital Corporation
- Glycan-shielded cd24 epitopes and uses thereof30 Oct 2025US 2025/0333532 A1Children's Research Institute, Children's National Medical Center
Most cited
By later US patents
- Method for making variant secreted proteins with altered properties199US 5,223,408 AGenentech, Inc. · 1993
- Novel receptors for efficient determination of ligands and their antagonists or agonists158US 4,859,609 AGenentech, Inc. · 1989
- Method for making variant secreted proteins with altered properties76US 5,736,135 AGenentech, Inc. · 1998
- Receptors for efficient determination of ligands and their antagonists or agonists67US 5,030,576 AGenentech, Inc. · 1991
- Preparation and use of gene banks of synthetic human antibodies ("synthetic human-antibody libraries")62US 5,840,479 ABehring Diagnostics GmbH · 1998